Related Experiment Video
Updated: May 18, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Stromal cell derived factor-1 (SDF-1) targeting reperfusion reduces myocardial infarction in isolated rat hearts
Young-Ho Jang1, June-Hong Kim, Changill Ban
1Cardiovascular Research Institute, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan-city, Gyungsangnam-do, Republic of Korea.
Insights
Stromal cell derived factor-1 (SDF-1) protects the heart during reperfusion injury, independent of stem cell recruitment. This cytokine significantly reduces infarct size, offering potential therapeutic benefits for myocardial infarction patients.
Area of Science:
- Cardiovascular Research
- Ischemia-Reperfusion (I/R) Injury
- Cytokine Signaling
Background:
- Stromal cell derived factor-1 (SDF-1) is a cytokine known for stem cell recruitment.
- Previous studies indicated SDF-1 confers myocardial protection against ischemia-reperfusion (I/R) injury.
- Prior research models involved preischemic exposure, limiting clinical relevance for therapeutic use.
Purpose of the Study:
- To evaluate the cardioprotective effects of SDF-1 during the reperfusion period following myocardial infarction.
- To determine if SDF-1 administration during reperfusion can mitigate I/R injury.
- To compare the efficacy of SDF-1 during reperfusion with preischemic exposure and ischemic conditioning.
Main Methods:
- Isolated rat hearts were perfused using the Langendorff system.
- Myocardial I/R injury was induced by left coronary artery ligation and subsequent reperfusion.
- SDF-1 was administered during the reperfusion period; infarct size (Area of Necrosis/Area at Risk) was quantified.
Main Results:
- SDF-1 significantly reduced the infarct size (AN/AR) in a dose-dependent manner during reperfusion.
- High-concentration SDF-1 (25 nM/L) infusion during reperfusion achieved greater infarct size reduction than ischemic pre- or postconditioning.
- Cardioprotection observed during reperfusion was comparable to that seen with preischemic SDF-1 exposure.
Conclusions:
- SDF-1 confers significant cardioprotection against I/R injury when administered during the reperfusion phase.
- The cardioprotective mechanism of SDF-1 in this context is not dependent on stem cell recruitment.
- SDF-1 demonstrates potential as a therapeutic agent for reducing myocardial I/R injury in clinical settings.
Abstract:
Recent studies have shown that stromal cell derived factor-1 (SDF-1), first known as a cytokine involved in recruiting stem cells into injured organs, confers myocardial protection in myocardial infarction, which is not dependent on stem cell recruitment but related with modulation of ischemia-reperfusion (I/R) injury. However, the effect of SDF has been studied only in a preischemic exposure model, which is not clinically relevant if SDF is to be used as a therapeutic agent. Our study was aimed at evaluating whether or not SDF-1 confers cardioprotection during the reperfusion period. Hearts from SD rats were isolated and perfused with the Langendorff system. Proximal left coronary artery ligation, reperfusion, and SDF perfusion in KH buffer was done according to study protocol. Area of necrosis (AN) relative to area at risk (AR) was the primary endpoint of the study. Significant reduction of AN/AR by SDF in an almost dose-dependent manner was noted during both the preischemic exposure and reperfusion periods. In particular, infusion of a high concentration of SDF (25 nM/L) resulted in a dramatic reduction of infarct size, which was greater than that achieved with ischemic pre- or postconditioning. SDF perfusion during reperfusion was associated with a similar significant reduction of infarct size as preischemic SDF exposure. Further studies are warranted to assess the potential of SDF as a therapeutic agent for reducing I/R injury in clinical practice.
